MONMOUTH JUNCTION, N.J., Nov. 21, 2014 /PRNewswire/ -- CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® cytokine adsorber to treat critically-ill patients in multiple countries worldwide, was awarded the Beacon of Light Award at last night’s New Jersey Tech Council Annual Awards Celebration.
Dr. Phillip Chan, Chief Executive Officer of CytoSorbents stated, “It is an honor to be recognized by the New Jersey Tech Council and the judging committee as the winner of the Beacon of Light award. At the company, we are all driven by the desire to help give critically-ill patients a fighting chance to survive life-threatening illnesses such as sepsis, trauma, lung injury, burn injury, and pancreatitis. To shine a guiding light and offer hope to physicians, patients and their families, where today there is still so much darkness.”
Dr. Chan continued, “We are grateful that CytoSorb® is being used by a growing number of physicians in many hospitals around the world to help stabilize patients in the intensive care unit and during high risk cardiac surgery. The goal is to prevent or treat multiple-organ failure, the leading cause of death in the ICU for which there is little to no effective treatment. This award is dedicated to the tireless efforts of the CytoSorbents team - from its internal leadership to its manufacturing, research and development, quality control, and sales and marketing departments - as well as to the Company’s shareholders, distributors, and strategic partners whose support we truly appreciate.”
About the New Jersey Tech Council
The New Jersey Tech Council is a not-for-profit, trade association focused on connecting decision-makers and thought-leaders from life sciences, technology, and technology support companies through access to financing opportunities, networking, and business support. With an active calendar of events and programs more than 100 opportunities to connect with peers, potential clients, strategic partners, vendors and employment prospects the New Jersey Tech Council provides vital business information to help its members grow and flourish. With more than 900 member businesses, ranging from small to large well-known corporations such as Verizon, Comcast, Qualcomm, and PSE&G, the New Jersey Tech Council supports a vibrant business community in New Jersey.
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company’s flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine adsorber, designed to reduce the “cytokine storm” that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.
CytoSorbents’ purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company’s website: http://www.cytosorbents.com/.
Forward-Looking Statements
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as “may,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management’s current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2014, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
Please Click to Follow us on Facebook and Twitter
Logo - http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
SOURCE CytoSorbents Corporation
Help employers find you! Check out all the jobs and post your resume.
